This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Soomro, H. Articles by Davies, N. Search for Related Content Social Bookmarking                         What's this?

Quantifying changes in retinal anatomy after interventions for diabetic maculopathy

Department of Ophthalmology, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK, hibba{at}doctors.org.uk

Lesley Burnett

Nigel Davies

Introduction

Diabetic maculopathy remains the major cause of loss of vision in diabetes. There is evidence to show that control of lipid levels reduces the amount of exudate in diabetic maculopathy, but to date there is no information on the effect of lipid reduction on diabetic macular oedema.

Purpose

The purpose of this case series was to compare retinal thickness using optical coherence tomography (OCT) of patients with exudative diabetic maculopathy whose only change in management was starting statins or increasing the current dose.

MethodsV"

Four patients with exudative diabetic maculopathy had serial OCT measurements to assess retinal thickness M before and after commencing or increasing their statin dose. Results

Analysis showed a reduction of macula thickness in all cases. Visual acuity also improved during the time course of the measurements.

Conclusion

Statins may aid management of diabetic maculopathy by reducing macular oedema. This case series gives the first quantified evidence of the effect of statins on reduction of diabetic macular oedema.

Key Words: Exudative diabetic maculopathy • optical coherence tomography • statins.

References

• Yu DY, Cringle SJ, Su EN et al. Pathogenesis and intervention strategies in diabetic retinopathy. Clin Experimental Ophthalmol 2001; 29:164-6.[CrossRef]
• Zander E., Herfurth S., Bohl B. et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol 2000;84:871-6.[Abstract/Free Full Text]
• Su DH, Yeo KT Diabetic retinopathy and serum lipids. Singapore Med J 2000;41:295-7.[Medline] [Order article via Infotrieve]
• Cuswick M., Chew EY, Chan CC et al. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003;110:2126-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gupta A., Gupta V., Tharphar S., Bansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-82.[Web of Science][Medline] [Order article via Infotrieve]
• Baghdasarian SB, Jneid H., Hoogwerf BJ Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther 2004;26:337-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sheth HG, Aslam S., Davies N. Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. BMJ 2006;332:1272-3.[Free Full Text]
• Chew EY, Klein ML, Ferris FL 3rd et al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (EDTRS) Report 22. Arch Ophthalmol 1996;144:1079-84
• Stratton IM, Cull CA, Adler IA et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49:1761-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mohan R., Mahan V., Susheela L. et al. Increased LDL cholesterol in non-insulin-dependent diabetics with maculopathy. Acta Diabetol Lat 1984;21:85-9.[Web of Science][Medline] [Order article via Infotrieve]
• Klein R., Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244-9.[Abstract/Free Full Text]
• The Field study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomised controlled trial. Lancet 2005;366:1849-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Freyberger H., Schifferdecker E., Schatz H. Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipaemic agent. Med Klin (Munich) 1994;89:594-7.[Medline] [Order article via Infotrieve]
• Goebel W., Franke R. Retinal thickness in diabetic retinopathy: comparison of optical coherence tomography, the retinal thickness analyser and fundus photography. Retina 2006;26:49-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sandu SS, Birch MK Griffiths PG et al. Short-term effects of focal argon laser treatment in diabetic maculopathy as demonstrated by optical coherence tomography. Retina 2007;27:13-20[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 4, 181-185 (2007)
DOI: 10.1177/14746514070070040701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Soomro, H. Articles by Davies, N. Search for Related Content Social Bookmarking                         What's this?